Becton Dickinson to Separate From Bioscience and Diagnostic Solutions Business
Chief Executive Tom Polen said he believes the separation would help differentiate BD in the medical-technology industry, and allow the company to invest more in innovation and margin growth.
BD Announces Intent to Separate Biosciences and Diagnostic Solutions Business to Enhance Focus, Drive Growth and Unlock Value
BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced its board of directors has unanimously authorized BD management to pursue a plan to separate BD's Biosciences and Diagnostic Solutions business from the rest of BD to enhance strategic focus and growth-oriented investments and capital allocation for both BD and the separated business and enhance value creation for shareholders.
BD to separate Biosciences and Diagnostic Solutions business
The plan is to position the New BD as a differentiated MedTech leader and enable optimized investment to accelerate the innovation pipeline and ongoing margin enhancement through BD Excellence to further fund growth.
Becton Dickinson looks to separate life sciences unit
Becton Dickinson said on Wednesday its board has authorized a plan to separate its life sciences unit as the medical device maker aims to focus on its core business.
Becton Dickinson committed to exploring all opportunities to execute separation
EST Becton Dickinson (BDX) committed to exploring all opportunities to execute separationMaximize Your Portfolio with Data Driven
Becton Dickinson reports Q1 adjusted EPS $3.43, consensus $2.99
Reports Q1 revenue $5.2B, consensus $5.11B. “We delivered strong operational performance in Q1, with revenue growth, margin expansion and ...
Becton Dickinson looks to divest life sciences unit at $30 billion valuation, source says
U.S. medical device maker Becton Dickinson is considering a potential separation of its life sciences unit at a valuation of ...
Zacks.com on MSN6h
Compared to Estimates, Becton Dickinson (BDX) Q1 Earnings: A Look at Key Metrics
While the top- and bottom-line numbers for Becton Dickinson (BDX) give a sense of how the business performed in the quarter ended December 2024, it could be worth looking at how some of its key ...
Becton Dickinson & Co. stock outperforms competitors on strong trading day
Becton Dickinson & Co. closed 2.75% below its 52-week high of $251.99, which the company reached on February 3rd.
Becton, Dickinson and Company (NYSE:BDX) Receives Average Recommendation of “Buy” from Analysts
Shares of Becton, Dickinson and Company (NYSE:BDX – Get Free Report) have earned an average rating of “Buy” from the seven ratings firms that are presently covering the company, MarketBeat.com reports ...
Seeking Alpha5d
BDX Becton, Dickinson and Company
Becton, Dickinson and Company develops ... and the general public worldwide. The BD Medical segment provides peripheral intravenous (IV) and advanced peripheral catheters, central lines, acute ...
American Association of Individual Investors6d
Which Is a Better Investment, Becton, Dickinson and Company or Intuitive Surgical, Inc. Stock?
Learn more about whether Becton, Dickinson and Company or Intuitive Surgical, Inc. is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial metrics.
Zawya9d
BD to showcase medtech innovations and signature programmes at Arab Health 2025
Company will spotlight sustainable solutions to enhance patient safety, workforce well-being, and care delivery efficiency ...
Becton Dickinson to separate biosciences, diagnostic solutions business
BD announced its board of directors has unanimously authorized BD management to pursue a plan to separate BD’s Biosciences and Diagnostic ...
BD (BDX) To Report Earnings Tomorrow: Here Is What To Expect
Medical technology company Becton, Dickinson and Company (NYSE:BDX) will be announcing earnings results tomorrow before market open. Here’s what to look for.